Koichi Takayama

Has grant

Professor

Kyoto Prefectural University of Medicine

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Koichi Takayama is a Professor at Kyoto Prefectural University of Medicine, Japan. His research focuses on the fields of oncology and immunotherapy, with recent articles addressing topics such as the prognostic implications of psoas muscle loss in lung cancer treatment and resistance patterns in patients with Coronavirus Disease 2019. He has contributed significantly to the understanding of various therapeutic strategies for non-small cell lung cancer, including chemoimmunotherapy and resistance to targeted therapies.

Recent Grants

Grant: Close

Development of novel therapy and diagnosis targeted for signal transduction regarding drug tolerance in lung cancer

Open Date: 2019-04-01

Close Date: 2022-03-31

Grant: Close

Development of patient-derived cancer on-a-chip devices for cancer immunotherapy

Open Date: 2017-04-01

Close Date: 2020-03-31

Grant: Close

Analysis of molecular factor to influence of immuno-checkpoint inhibitor in lung cancer treatment

Open Date: 2016-04-01

Close Date: 2019-03-31

Grant: Close

Expression and functional analyses of R-spondin-Lgr6 signaling pathway in lung cancer

Open Date: 2014-04-01

Close Date: 2017-03-31

Grant: Close

Genome epidemiologic study on lung cancer and estrogen-related genes.

Open Date: 2013-04-01

Close Date: 2017-03-31

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Koichi Takayama

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019

The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study

Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study

Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.

Collaborators (5)

Junji Uchino

Akihiro Yoshimura

Satomi Morita

JUNYA KURODA

Hiroyuki Yamaguchi

Make your next move.